Jeffrey R Vittengl1, Lee Anna Clark2, Michael E Thase3, Robin B Jarrett4. 1. Department of Psychology, Truman State University. 2. Department of Psychology, University of Notre Dame. 3. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania. 4. Department of Psychiatry, The University of Texas Southwestern Medical Center.
Abstract
OBJECTIVE: Acute-phase cognitive therapy (CT) is an efficacious treatment for major depressive disorder (MDD) producing benefits comparable to pharmacotherapy, but not all patients respond or remit. The purpose of the current analyses was to estimate CT patients' probability of nonresponse and remission from symptom improvement early in treatment. METHOD: Data from 2 clinical trials of acute-phase CT for recurrent depression were pooled for analysis (N = 679). Adult outpatients received 16- or 20-session CT protocols. Symptoms were measured repeatedly with the clinician-report Hamilton Rating Scale for Depression (HRSD) and Inventory of Depressive Symptomatology-Self-Report (IDS-SR). Outcomes at exit from CT were nonresponse (<50% reduction in HRSD scores) and remission (no MDD and HRSD score ≤6). RESULTS: The nonresponse rate was 45.7%, and the remission rate was 33.4%. In logistic regression models, improvements on the HRSD or IDS-SR from intake to CT Sessions 3, 5, 7, 9, or 11 significantly predicted both outcomes, with prediction gaining in accuracy in later sessions. Clinician and self-report assessments yielded similar results. Prediction of outcomes replicated across data sets. Patients with no symptom improvement by CT Session 9 (Week 5) had ≤10% probability of remission and >75% probability of nonresponse. CONCLUSIONS: Outcomes of CT for depression are predictable from early symptom changes. Clinicians may find nonresponse and remission probability estimates useful in the informed consent process and in choosing whether to continue, augment, or switch treatments for CT patients with recurrent MDD. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
OBJECTIVE: Acute-phase cognitive therapy (CT) is an efficacious treatment for major depressive disorder (MDD) producing benefits comparable to pharmacotherapy, but not all patients respond or remit. The purpose of the current analyses was to estimate CT patients' probability of nonresponse and remission from symptom improvement early in treatment. METHOD: Data from 2 clinical trials of acute-phase CT for recurrent depression were pooled for analysis (N = 679). Adult outpatients received 16- or 20-session CT protocols. Symptoms were measured repeatedly with the clinician-report Hamilton Rating Scale for Depression (HRSD) and Inventory of Depressive Symptomatology-Self-Report (IDS-SR). Outcomes at exit from CT were nonresponse (<50% reduction in HRSD scores) and remission (no MDD and HRSD score ≤6). RESULTS: The nonresponse rate was 45.7%, and the remission rate was 33.4%. In logistic regression models, improvements on the HRSD or IDS-SR from intake to CT Sessions 3, 5, 7, 9, or 11 significantly predicted both outcomes, with prediction gaining in accuracy in later sessions. Clinician and self-report assessments yielded similar results. Prediction of outcomes replicated across data sets. Patients with no symptom improvement by CT Session 9 (Week 5) had ≤10% probability of remission and >75% probability of nonresponse. CONCLUSIONS: Outcomes of CT for depression are predictable from early symptom changes. Clinicians may find nonresponse and remission probability estimates useful in the informed consent process and in choosing whether to continue, augment, or switch treatments for CT patients with recurrent MDD. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
Authors: Manuel Trachsel; Martin Grosse Holtforth; Nikola Biller-Andorno; Paul S Appelbaum Journal: Lancet Psychiatry Date: 2015-09 Impact factor: 27.083
Authors: Julian Rubel; Wolfgang Lutz; Stephen Mark Kopta; Katharina Köck; Takuya Minami; Dirk Zimmermann; Stephen M Saunders Journal: Psychol Assess Date: 2014-12-15
Authors: Mauricio Tohen; Michael Case; Madhukar H Trivedi; Michael E Thase; Scott J Burke; Todd M Durell Journal: J Clin Psychiatry Date: 2010-02-23 Impact factor: 4.384
Authors: Erica S Weitz; Steven D Hollon; Jos Twisk; Annemieke van Straten; Marcus J H Huibers; Daniel David; Robert J DeRubeis; Sona Dimidjian; Boadie W Dunlop; Ioana A Cristea; Mahbobeh Faramarzi; Ulrich Hegerl; Robin B Jarrett; Farzan Kheirkhah; Sidney H Kennedy; Roland Mergl; Jeanne Miranda; David C Mohr; A John Rush; Zindel V Segal; Juned Siddique; Anne D Simons; Jeffrey R Vittengl; Pim Cuijpers Journal: JAMA Psychiatry Date: 2015-11 Impact factor: 21.596
Authors: Robin B Jarrett; Abu Minhajuddin; Howard Gershenfeld; Edward S Friedman; Michael E Thase Journal: JAMA Psychiatry Date: 2013-11 Impact factor: 21.596
Authors: A John Rush; Harold A Sackeim; Charles R Conway; Mark T Bunker; Steven D Hollon; Koen Demyttenaere; Allan H Young; Scott T Aaronson; Maxine Dibué; Michael E Thase; R Hamish McAllister-Williams Journal: Psychol Med Date: 2022-01-07 Impact factor: 7.723